Research programme: anti-fibrotic therapeutics - ConnexiosAlternative Names: CNX-014; CNX-023; CNX-024; CNX-025
Latest Information Update: 15 Oct 2015
At a glance
- Originator Connexios Life Sciences
- Mechanism of Action G protein-coupled receptor modulators; Mitogen-activated protein kinase modulators; Peptide hydrolase modulators; Protein kinase modulators; Protein tyrosine kinase modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Fibrosis
Most Recent Events
- 15 Oct 2015 Early research in Fibrosis in India before October 2015 (unspecified route)